image
Healthcare - Biotechnology - NASDAQ - US
$ 17.39
1.46 %
$ 133 M
Market Cap
-2.8
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ASMB stock under the worst case scenario is HIDDEN Compared to the current market price of 17.4 USD, Assembly Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ASMB stock under the base case scenario is HIDDEN Compared to the current market price of 17.4 USD, Assembly Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ASMB stock under the best case scenario is HIDDEN Compared to the current market price of 17.4 USD, Assembly Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ASMB

image
$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
28.5 M REVENUE
298.16%
-45.4 M OPERATING INCOME
29.74%
-40.2 M NET INCOME
34.38%
-51.1 M OPERATING CASH FLOW
-224.76%
40.2 M INVESTING CASH FLOW
158.10%
29.4 M FINANCING CASH FLOW
113.12%
9.42 M REVENUE
28.03%
-9.94 M OPERATING INCOME
13.80%
-8.82 M NET INCOME
14.68%
-23.4 M OPERATING CASH FLOW
-5658.97%
6.59 M INVESTING CASH FLOW
198.36%
1.92 M FINANCING CASH FLOW
-88.69%
Balance Sheet Assembly Biosciences, Inc.
image
Current Assets 116 M
Cash & Short-Term Investments 112 M
Receivables 0
Other Current Assets 3.42 M
Non-Current Assets 3.66 M
Long-Term Investments 0
PP&E 3.35 M
Other Non-Current Assets 312 K
94.05 %2.87 %2.81 %Total Assets$119.2m
Current Liabilities 47.8 M
Accounts Payable 585 K
Short-Term Debt 461 K
Other Current Liabilities 46.8 M
Non-Current Liabilities 38 M
Long-Term Debt 5.26 M
Other Non-Current Liabilities 32.8 M
54.49 %6.13 %38.17 %Total Liabilities$85.8m
EFFICIENCY
Earnings Waterfall Assembly Biosciences, Inc.
image
Revenue 28.5 M
Cost Of Revenue 0
Gross Profit 28.4 M
Operating Expenses 73.9 M
Operating Income -45.4 M
Other Expenses -5.24 M
Net Income -40.2 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)29m028m(74m)(45m)5m(40m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
99.55% GROSS MARGIN
99.55%
-159.26% OPERATING MARGIN
-159.26%
-140.87% NET MARGIN
-140.87%
-120.44% ROE
-120.44%
-33.71% ROA
-33.71%
-63.76% ROIC
-63.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Assembly Biosciences, Inc.
image
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -40.2 M
Depreciation & Amortization 129 K
Capital Expenditures -28 K
Stock-Based Compensation 3.12 M
Change in Working Capital -11.9 M
Others -14.4 M
Free Cash Flow -51.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Assembly Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for ASMB of $35.5 , with forecasts ranging from a low of $35 to a high of $36 .
ASMB Lowest Price Target Wall Street Target
35 USD 101.27%
ASMB Average Price Target Wall Street Target
35.5 USD 104.14%
ASMB Highest Price Target Wall Street Target
36 USD 107.02%
Price
Max Price Target
Min Price Target
Average Price Target
404035353030252520201515101055Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Assembly Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
14.7 K USD 4
6-9 MONTHS
5.89 K USD 2
9-12 MONTHS
25.1 K USD 2
Bought
0 USD 0
0-3 MONTHS
50 K USD 1
3-6 MONTHS
20.6 M USD 2
6-9 MONTHS
112 K USD 1
9-12 MONTHS
7. News
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations. globenewswire.com - 1 month ago
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago. zacks.com - 1 month ago
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates – Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – globenewswire.com - 1 month ago
New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 – Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 – SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the European Association for the Study of the Liver (EASL) Congress, taking place May 7-10, 2025, in Amsterdam, the Netherlands. globenewswire.com - 1 month ago
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 1 month ago
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress – Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – globenewswire.com - 2 months ago
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 2 months ago
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights – Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – globenewswire.com - 3 months ago
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus – Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate. globenewswire.com - 4 months ago
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes – ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – globenewswire.com - 4 months ago
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B – ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – globenewswire.com - 6 months ago
8. Profile Summary

Assembly Biosciences, Inc. ASMB

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 133 M
Dividend Yield 0.00%
Description Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Contact 331 Oyster Point Boulevard, South San Francisco, CA, 94080 https://www.assemblybio.com
IPO Date Dec. 17, 2010
Employees 73
Officers Dr. William E. Delaney IV, Ph.D. Chief Scientific Officer Mr. Shannon Ryan Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR Chief Human Resources Officer Dr. Anuj Gaggar M.D., Ph.D. Chief Medical Officer Amy Figueroa C.F.A. Investor Relations Consultant Ms. Jeanette M. Bjorkquist Executive Director of Accounting & Treasury Mr. Thomas E. Rollins Executive Officer Mr. Jason A. Okazaki J.D. Chief Executive Officer, President & Director Dr. Nicole S. White Ph.D. Chief Manufacturing Officer